Italia markets closed

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,0800+0,0050 (+6,91%)
In data: 01:25PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,0750
Aperto0,0730
Denaro0,2100 x 800
Lettera0,2050 x 800
Min-Max giorno0,0730 - 0,0800
Intervallo di 52 settimane0,0520 - 1,2990
Volume57.089
Media Volume8.563.675
Capitalizzazione3,17M
Beta (5 anni mensile)1,17
Rapporto PE (ttm)N/D
EPS (ttm)-2,5000
Prossima data utili28 mar 2024 - 01 apr 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A5,50
  • GlobeNewswire

    Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

    SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, whic

  • GlobeNewswire

    Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring

    Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the sec

  • GlobeNewswire

    Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting

    Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human